High-dose weekly amBisome antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: A pharmacokinetic study

Biology of Blood and Marrow Transplantation

Volumn 12, Issue 2, 2006, Pages 235-240

  Mehta, Parinda ^a   Vinks, Alexander ^a   Filipovich, Alexandra ^a   Vaughn, Gretchen ^a   Fearing, Deborah ^a   Sper, Christine ^a   Davies, Stella ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

Author keywords

AmBisome; Fungal prophylaxis; Hematopoietic stem cell transplantation; Pharmacokinetics

Indexed keywords

ALKALINE PHOSPHATASE; AMINOTRANSFERASE; AMPHOTERICIN B LIPID COMPLEX; CREATININE;

ALKALINE PHOSPHATASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; CHILD HEALTH CARE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG INFUSION; DRUG MEGADOSE; DRUG TOLERABILITY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPOKALEMIA; HYPOMAGNESEMIA; INFANT; INFECTION PREVENTION; LEG CRAMP; MALE; MATHEMATICAL MODEL; MULTIPLE DRUG DOSE; MYCOSIS; PRESCHOOL CHILD; SINGLE DRUG DOSE; STEADY STATE;

AMPHOTERICIN B; ANTIBIOTICS, ANTIFUNGAL; ANTIFUNGAL AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HEMATOLOGIC DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; MALE; MYCOSES; PROSPECTIVE STUDIES; TIME FACTORS;

EID: 31344451094     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2005.10.010     Document Type: Article

References (30)

1. S. Abbasi J.L. Shenep W.T. Hughes et al. Aspergillosis in children with cancer: A 34-year experience Clin Infect Dis 29 1999 1210-1219
2. A.H. Groll F.M. Müller S.C. Piscitelli et al. Lipid formulations of amphotericin B: Clinical perspectives for the management of invasive fungal infections in children with cancer Klin Pädiatr 210 1998 264-273
3. O. Ringden E.E. Andstrom M. Remberger et al. Prophylaxis and therapy using liposomal amphotericin B (AmBisome) for invasive fungal infections in children undergoing organ or allogeneic bone-marrow transplantation Pediatr Transplant 1 1997 124-129
4. L. Hovi U.M. Saarinen-Pihkala K. Vettenranta et al. Invasive fungal infections in pediatric bone marrow transplant recipients: Single-center experience of 10 years Bone Marrow Transplant 26 2000 999-1004
5. M.A. Pfaller D.J. Diekema R.N. Jones et al. Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections SENTRY Antimicrobial Surveillance Program, 1997 to 2000 J Clin Microbiol 40 2002 852-856
6. C.A. Mullen H. Abd El-Baki H. Samir et al. Non-albicans Candida is the most common cause of candidemia in pediatric cancer patients Support Care Cancer 11 2003 321-325
7. A.H. Groll M. Kurz W. Schneider et al. Five-year-survey of invasive aspergillosis in a paediatric cancer centre: Epidemiology, management and long-term survival Mycoses 42 1999 431-442
8. T.J. Walsh A. Groll J. Hiemenz et al. Infections due to emerging and uncommon medically important fungal pathogens Clin Microbiol Infect 10 2004 48-66
9. F. Menichetti A. Del Favero P. Martino et al. Gruppo Italiano Malattie Ematologiche dell'Adulto Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. GIMEMA Infection Program Clin Infect Dis 28 1999 250-255
10. G.P. Bodey E.J. Anaissie L.S. Elting et al. Antifungal prophylaxis during remission induction therapy for acute leukemia fluconazole versus intravenous amphotericin B Cancer 73 1994 2099-2106
11. C.A. Lyman T.J. Walsh Systemically administered antifungal agents: A review of their clinical pharmacology and therapeutic applications Drugs 44 1992 935
12. I. Bekersky D. Buell M. Tomishima et al. New approaches to systemic antifungal therapy: Case studies of AmBisome and FK463 Recent Res Dev Antimicrob Agent Chemother 3 1999 407-413
13. G.W. Boswell D. Buell I. Bekersky et al. AmBisome (liposomal amphotericin B): A comparative review J Clin Pharmacol 38 1998 583-592
14. T.J. Walsh R.W. Fineberg C. Arndt et al. Liposomal amphotricin B for empiric therapy in patients with persistent fever and neutropenia N Engl J Med 340 1999 764-771
15. I. Bekersky G.W. Boswell R. Hiles et al. Safety and toxicokinetics of intravenous liposomal amphotericin B (AmBisome) in beagle dogs Pharm Res 16 1999 1694-1701
16. I. Bekersky G.W. Boswell R. Hiles et al. Safety, toxicokinetics, and tissue distribution of long-term intravenous liposomal amphotericin B (AmBisome): A 91-day study in rats Pharm Res 17 2000 1494-1502
17. G.W. Boswell I. Bekersky D. Buell et al. Toxicological profile and pharmacokinetics of a unilamellar liposomal vesicle formulation of amphotericin B in rats Antimicrob Agents Chemother 42 1998 263-268
18. J.W. Lee M. Amantea E. Navarro et al. Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits Antimicrob Agents Chemother 38 1994 713-718
19. T.J. Walsh V. Yeldandi M. McEvoy et al. Safety, tolerance and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients Antimicrob Agents Chemother 42 1998 2391-2398
20. S.M. Kelsey J.M. Goldman S. McCann et al. Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: A randomized, double-blind, placebo-controlled study Bone Marrow Transplant 23 1999 163-168
21. J. Tollemar O. Ringdeń S. Anderson et al. Randomized double-blind study of liposomal amphotericin B (AmBisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients Bone Marrow Transplant 12 1993 577-582
22. J. Tollemar K. Hoc̈kerstedt B.G. Ericzon et al. Liposomal amphotericin B prevents invasive fungal infections in liver transplant recipients Transplantation 59 1995 45-50
23. K.V. Clemons R.A. Sobel P.L. Williams et al. Efficacy of intravenous liposomal amphotericin B (AmBisome) against coccidioidal meningitis in rabbits Antimicrob Agents Chemother 46 2002 2420-2426
24. I. Bekersky R.M. Fielding D.E. Dressler et al. Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans Antimicrob Agents Chemother 46 2002 828-833
25. A. Garcia J.P. Adler-Moore R. Proffitt Single-dose AmBisome (liposomal amphotericin B) as prophylaxis for murine systemic candidiasis and histoplasmosis Antimicrob Agents Chemother 44 2000 2327-2332
26. te Dorsthorst DT, Verweij PE, Meis JF, et al. Efficacy of one-day versus seven-day ambisome treatment in a non-neutropenic murine model of invasive aspergillosis. In Program and Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, October 12-November 2, 2004. Washington, DC. p. 39.
27. D. Andes T. Stamsted R. Conklin Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model Antimicrob Agents Chemother 45 2001 922-926
28. D. Andes Clinical utility of antifungal pharmacokinetics and pharmacodynamics Curr Opin Infect Dis 17 2004 533-540
29. Gubbins PO, Mcconnell SA, Amsden JR, et al. Comparison of liposomal amphotericin B plasma and tissue concentrations following a single large (15 mg/kg) dose or daily 1 mg/kg dosing. Poster presentation at the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, October 12-November 2, 2004.
30. T.J. Walsh J.L. Goodman P. Pappas et al. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study Antimicrob Agents Chemother 45 2001 3487-3496